Valuation: Caris Life Sciences, Inc.

Market Cap 4.8B 4.2B 3.87B 3.58B 6.79B 458B 6.9B 46.3B 18.18B 226B 18.03B 17.64B 776B P/E 2026 *
168x
P/E 2027 * 52.5x
Enterprise Value 4.37B 3.82B 3.53B 3.26B 6.18B 417B 6.28B 42.14B 16.55B 205B 16.41B 16.06B 706B EV / Sales 2026 *
4.36x
EV / Sales 2027 * 3.47x
Free-Float
51.2%
Yield 2026 *
-
Yield 2027 * -
Jul. 01 Caris Life Sciences Launches Caris Detect Multi-Cancer Early Detection Blood Test CI
Jun. 08 Caris Life Sciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 10:40 AM
Jun. 08 Caris Life Sciences, Inc. authorizes a Buyback plan. CI
Jun. 08 Caris Life Sciences, Inc. announces an Equity Buyback for $100 million worth of its shares. CI
May. 22 Caris Life Sciences Presents 32 Studies At Asco 2026 Highlighting Advances in Multi-Omic Biomarker Research and Real-World Evidence CI
May. 15 Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris Mi Cancer Seek CI
May. 12 Caris Life Sciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:00 AM
May. 12 Caris Life Sciences Insider Bought Shares Worth $501,426, According to a Recent SEC Filing MT
May. 11 Caris Life Sciences Publishes Study Showing Whole Exome Measurement Of Tumor Mutational Burden Results In Increased Overall Survival Compared To Estimates From Targeted Gene Panels CI
May. 08 Caris Life Sciences Submits Application for Molecular Profiling Test in New York State MT
May. 08 Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization CI
May. 07 Caris Life Sciences, Inc., Q1 2026 Earnings Call, May 07, 2026
May. 07 Caris Life Sciences Reports Q1 Breakeven Results, Revenue Rises; 2026 Guidance Reaffirmed MT
1 day-4.92%
1 week-7.16%
Current month-4.66%
1 month-0.99%
3 months-5.87%
6 months-40.41%
Current year-37.03%
1 week 16.73
Extreme 16.73
18.8
1 month 16.73
Extreme 16.73
19.97
Current year 14.19
Extreme 14.19
29.32
1 year 14.19
Extreme 14.19
42.5
3 years 14.19
Extreme 14.19
42.5
5 years 14.19
Extreme 14.19
42.5
10 years 14.19
Extreme 14.19
42.5
Manager TitleAgeSince
Chief Executive Officer 70 2007-12-31
Director of Finance/CFO 45 2023-01-31
President 50 2016-10-31
Director TitleAgeSince
Chairman 70 2007-12-31
Director/Board Member 60 2007-12-31
Director/Board Member 66 2014-04-30
Date Insider Type Main position Quantity % Market Cap.
May. 28Free

Director

1,600 0.0006%
May. 28Free

Chief Technology Officer

1,600 0.0006%
May. 14Tax

Chief Executive Officer

-40,712 0.0145%
Change 5-day change 1-year change 3-year change Capi.($)
-4.92%-7.16%-36.18% - 4.8B
-2.46%-4.72%+212.05%+318.32% 21.22B
-2.58%+0.14%-42.60%-22.89% 9.41B
-0.33%-3.87%+26.02%+24.49% 6.88B
-0.86%+9.54%+238.59%-26.38% 5.42B
+3.74%-1.63%-21.48%-28.55% 5.05B
-1.04%-1.40%-24.44%-24.84% 4.17B
+0.75%-11.50%+60.79%+69.60% 3.64B
+0.62%-0.77%-18.44%-39.92% 2.59B
+3.72%+1.08%-34.54%+194.06% 1.61B
Average -0.34%-1.73%+35.98%+51.54% 6.48B
Weighted average by Cap. -1.27%-1.90%+81.88%+113.00%

Financials

2026 *2027 *
Net sales 1B 877M 809M 747M 1.42B 95.64B 1.44B 9.67B 3.8B 47.11B 3.77B 3.68B 162B 1.2B 1.05B 969M 895M 1.7B 115B 1.73B 11.58B 4.55B 56.44B 4.51B 4.41B 194B
Net income 28.98M 25.35M 23.38M 21.59M 40.97M 2.76B 41.66M 279M 110M 1.36B 109M 106M 4.68B 97.94M 85.67M 79.02M 72.98M 138M 9.34B 141M 944M 371M 4.6B 368M 360M 15.82B
Net Debt -431M -377M -348M -321M -610M -41.14B -620M -4.16B -1.63B -20.26B -1.62B -1.58B -69.67B -636M -556M -513M -474M -899M -60.66B -914M -6.13B -2.41B -29.88B -2.39B -2.34B -103B
Logo Caris Life Sciences, Inc.
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Employees
1,846
Date Price Change Volume
26-07-10 $16.99 -4.92% 2,258,712
26-07-09 $17.87 +3.18% 3,294,445
26-07-08 $17.32 -0.86% 2,825,875
26-07-07 $17.47 -1.91% 2,677,555
26-07-06 $17.81 -2.68% 2,611,052
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
16.99USD
Average target price
27.42USD
Spread / Average Target
+61.37%

Quarterly revenue - Rate of surprise